A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects

Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT05069870
Collaborator
(none)
42
1
3
4.8
8.7

Study Details

Study Description

Brief Summary

This is a three-part, single-center, open-label phase I clinical study to characterize the DDIs potential of SKLB1028 with Itraconazole, Gemfibrozil or Rifampicin in healthy subjects. This study also aims to evaluate the safety and tolerability of SKLB1028 in the presence of Itraconazole, Gemfibrozil or Rifampicin.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

SKLB1028 is the potential substrate of CYP3A4, CYP2C8 and P-gp. This study conducted in three parts to characterize the DDIs potential of SKLB1028 with the perpetrator drugs ( Itraconazole, Gemfibrozil, Rifampicin) in Healthy Subjects. Each part of this study consists of a screening period (Day -14 to Day -2), a baseline period (Day -1), a treatment period, and a follow-up visit period.

Study Design

Study Type:
Interventional
Actual Enrollment :
42 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Three-part, Single-center, Open-label, Phase I Drug-drug Interaction Clinical Study to Investigate the Effect of Itraconazole, Gemfibrozil or Rifampicin on Pharmacokinetics of SKLB1028 in Healthy Subjects
Actual Study Start Date :
Jun 7, 2021
Anticipated Primary Completion Date :
Nov 1, 2021
Anticipated Study Completion Date :
Nov 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: The DDI of SKLB1028 and Itraconazole

Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Itraconazole 200 mg twice-daily on Day 8 and 200 mg once-daily on Day 9 through Day 18, and took a single dose of SKLB1028 100 mg on Day 11.

Drug: SKLB1028
SKLB1028, capsule, oral

Drug: Itraconazole
Itraconazole, capsule, oral

Experimental: The DDI of SKLB1028 and Gemfibrozil

Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Gemfibrozil 600 mg twice-daily on Day 8 through Day 19, and took a single dose of SKLB1028 100 mg on Day 12.

Drug: SKLB1028
SKLB1028, capsule, oral

Drug: Gemfibrozil
Gemfibrozil, capsule, oral

Experimental: The DDI of SKLB1028 and Rifampicin

Eligible subjects received a single dose of SKLB1028 150 mg on Day 1, then took Rifampicin 600 mg once-daily on Day 8 through Day22, and took a single dose of SKLB1028 150 mg on Day 15.

Drug: SKLB1028
SKLB1028, capsule, oral

Drug: Rifampicin
Rifampicin, capsule, oral

Outcome Measures

Primary Outcome Measures

  1. Maximum concentration (Cmax) of SKLB1028 [Up to 22 days]

  2. Area under the concentration-time curve (AUC) from 0 to the last measurable concentration (AUC0-t) of SKLB1028 [Up to 22 days]

  3. AUC extrapolated to infinity (AUCinf) of SKLB1028 [Up to 22 days]

Secondary Outcome Measures

  1. Time to Cmax (Tmax) of SKLB1028 [Up to 22 days]

  2. Terminal elimination half-life (t1/2) of SKLB1028 [Up to 22 days]

  3. Apparent Clearance (CLz/F) of SKLB1028 [Up to 22 days]

  4. Apparent volume of distribution (Vz/F) of SKLB1028 [Up to 22 days]

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [Up to approximately 30 days]

  6. Clinically significant changes from baseline in routine blood test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Routine blood test included cell count (white blood cells, platelets, basophils, eosinophils, neutrophils, lymphocytes and monocytes) in 10^9/L.

  7. Clinically significant changes from baseline in routine blood test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Routine blood test included red blood cell count in 10^12/L.

  8. Clinically significant changes from baseline in routine blood test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Routine blood test included hemoglobin in g/L.

  9. Clinically significant changes from baseline in blood biochemistry test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Blood biochemistry test included total bilirubin and serum creatinine in μmol/L.

  10. Clinically significant changes from baseline in blood biochemistry test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Blood biochemistry test included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and creatine kinase in U/L.

  11. Clinically significant changes from baseline in blood biochemistry test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Blood biochemistry test included total protein and albumin in g/L.

  12. Clinically significant changes from baseline in blood biochemistry test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Blood biochemistry test included total cholesterol, triglyceride and blood glucose in mmol/L.

  13. Clinically significant changes from baseline in routine urine test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Routine urine test included protein, urobilinogen, glucose and ketones (positive or negative).

  14. Clinically significant changes from baseline in routine urine test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Routine urine test included pH value and specific gravity.

  15. Clinically significant changes from baseline in coagulation function test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Coagulation function test included prothrombin time and activated partial thromboplastin time in seconds.

  16. Clinically significant changes from baseline in coagulation function test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Coagulation function test included antithrombin III as percentage.

  17. Clinically significant changes from baseline in coagulation function test were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Coagulation function test included fibrinogen in g/L.

  18. Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination were recorded as AEs at each visit time point. [Up to approximately 30 days]

    ECG monitoring included heart rate in bpm.

  19. Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination were recorded as AEs at each visit time point. [Up to approximately 30 days]

    ECG monitoring included P-R, QRS, QT and QTcF in ms.

  20. Clinically significant changes from baseline in vital signs examination were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Vital signs monitoring included body temperature in degrees Celsius.

  21. Clinically significant changes from baseline in vital signs examination were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Vital signs monitoring included respiratory rate and pulse in times per minute.

  22. Clinically significant changes from baseline in vital signs examination were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Vital signs monitoring included systolic blood pressure and diastolic blood pressure in mmHg.

  23. Clinically significant changes from baseline in physical examination were recorded as AEs at each visit time point. [Up to approximately 30 days]

    Physical examination included general conditions, skin, mucous membranes, head, neck, chest, abdomen, spine, limbs, nervous system, and lymphatic system.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Healthy subjects:
  1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;

  2. 18 ≤ age ≤45, male;

  3. Subjects with weight ≥50.0 kg and body mass index (BMI) 19-26 kg/m^2 (inclusive);

  4. Subjects are willing to use effective contraceptives and not allowed to donate sperm from screening to the 6 months after the last dose administration unless permanent contraception has been taken, such as vasectomy.

  5. Ability to communicate well with researchers, and be willing to comply with all trial requirements.

Exclusion Criteria:
  1. Allergic constitution, including a history of allergy to any of the study drugs or other similarly structured drugs;

  2. Previous or current severe diseases, such as cardiovascular, respiratory, gastrointestinal, endocrine, hematological, psychiatric/neurological systems diseases, or any other disease that can interfere with the results of the study;

  3. Subjects who have previously undergone surgery that may affect the absorption, distribution, metabolism, or excretion of the drug (e.g., subtotal gastrectomy), or who have a scheduled surgical plan during the study period;

  4. Use of any strong inhibitors or inducers of CYP3A4, CYP2C8 or P-gp within 2 weeks prior to screening;

  5. Use of any prescription drug, over-the-counter drug, herbal medicine or health products within 2 weeks prior to screening;

  6. History of drug abuse within 1 year prior to screening, or positive urine drug screen at screening;

  7. Smoking more than 5 cigarettes per day within 6 months prior to screening;

  8. Average daily intake of alcohol more than 14 units (14 units ≈285 mL of beer, or 25 mL of liquor, or 150 mL of wine) within 4 weeks prior to screening, or a positive ethanol breath test at screening;

  9. Consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 48 h before the administration, or those who have had strenuous exercise, or have other factors affecting absorption, distribution, metabolism, excretion, etc of the drug;

  10. Participation in another clinical trial within 3 months before screening (whichever is administrated);

  11. Blood donation (or blood loss) ≥200 mL within 4 weeks prior to the screening, or who have a blood donation plan during the entire study or within 1 months after the study;

  12. Any abnormalities of clinical significance in physical examination, vital signs, clinical laboratory tests (routine blood test, blood biochemistry, routine urine test, coagulation function), anteroposterior chest radiograph or chest CT scan;

  13. Abnormalities of clinical significance in 12-lead ECG examination (such as tachycardia/bradycardia in need of medical treatment, II-III degree atrioventricular block, QTcF>450 ms or any other clinically significant abnormalities );

  14. Any positive test result of hepatitis B surface antigen or hepatitis C virus antibody, or subjects with a history of hepatitis B;

  15. Any positive test result of anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific antibody;

  16. Any condition that, in the opinion of the Investigator, may prevent the subject from completing the study or poses a significant risk to the subject.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Friendship Hospital, Capital Medical University Beijing China

Sponsors and Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
ClinicalTrials.gov Identifier:
NCT05069870
Other Study ID Numbers:
  • HA114-CSP-009
First Posted:
Oct 6, 2021
Last Update Posted:
Oct 6, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 6, 2021